ROSE Diagnostics is a Carlsbad, California-based company developing point-of-care testing solutions intended to improve lung cancer biopsy outcomes. Its mission is to reduce the time and cost involved in reaching a diagnosis so patients can begin treatment sooner. In conventional biopsies, samples are sent to a pathology lab to confirm that suitable tissue was collected; when a sample is insufficient, patients may need another procedure. ROSE Diagnostics says this occurs in up to 40% of cases.

The company is developing a rapid test to assess specimens during the biopsy procedure and support real-time decisions. The test takes about five minutes and uses disposable cartridges containing a panel of known lymph node biomarkers, read by a small, portable, affordable reader. By checking sample adequacy during the procedure, the technology is intended to reduce or eliminate repeat biopsies, helping limit delays, medical costs, and patient anxiety. ROSE Diagnostics presents its products as part of a broader effort to improve the patient journey.